Modality
Gene Editing
MOA
PD-1i
Target
IL-17A
Pathway
Epigenetic
RA
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
Aug 2018
→ Apr 2026
Phase 2Current
NCT04586022
2,932 pts·RA
2018-08→2026-04·Terminated
2,932 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-203w awayPh3 Readout· RA
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2/3
Termina…
Catalysts
Ph3 Readout
2026-04-20 · 3w away
RA
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04586022 | Phase 2/3 | RA | Terminated | 2932 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A |